Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt Inc (ADTX) is a pioneering biotechnology company developing innovative solutions to reprogram immune responses, with applications in organ transplantation and autoimmune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic partnerships.
Access authoritative reporting on ADTX's flagship programs including Adimune for transplant tolerance and AditxtScore diagnostic platforms. Track developments in Apoptotic DNA Immunotherapy (ADi) and other novel approaches to immune modulation. The curated news feed covers earnings reports, research collaborations, and product pipeline updates while adhering to financial disclosure standards.
Bookmark this page for consolidated access to press releases, clinical trial data disclosures, and expert analyses of ADTX's position in the competitive immunotherapy landscape. Stay informed about technological breakthroughs through verified updates from primary sources.
Aditxt (NASDAQ: ADTX) has announced a 1-for-250 reverse stock split effective March 17, 2025, on the Nasdaq Capital Market. The split was approved by stockholders at a special meeting on February 28, 2025, with the final ratio determined by the board of directors.
Following the reverse split, every 250 shares of common stock will be consolidated into 1 share, with fractional shares rounded up. The company will maintain its ADTX trading symbol but will receive a new CUSIP number: 007025802. Post-split, Aditxt will have approximately 1,031,110 shares of common stock outstanding.
The primary purpose of this corporate action is to achieve compliance with Nasdaq's minimum bid price requirement.
Aditxt (NASDAQ: ADTX) subsidiary Adimune has completed preclinical studies for ADI-100, its investigational immune modulation therapy targeting Psoriasis, Type 1 Diabetes (T1D), and Stiff Person Syndrome. The company plans to ship drug substances for final formulation in March.
Key preclinical findings show:
- Durable tolerance restoration over 10-month T1D studies in prevention and treatment
- No drug toxicity or antibody formation
- No impairment of immune system response against infection, cancer, or tumor-fighting capabilities
GMP clinical-grade drug substances have been manufactured, with two remaining drug product release assays in final validation stages. Adimune has completed additional studies requested by German regulators and engaged a CRO for clinical trials in Germany. The company is also preparing an IND package for FDA submission, with a pre-IND meeting expected in Q2.
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities as lead underwriter for its planned IPO, targeted for H2 2025. The IPO aims to support Pearsanta's commercial launch of early cancer detection technology in the U.S. and internationally.
Pearsanta is developing a non-invasive blood-based test using proprietary Mitomic® Technology, which utilizes mitochondrial DNA deletions as biomarkers for disease detection. The company is currently advancing clinical validation, including a randomized controlled study of the Mitomic Prostate Test (MPT).
The company has submitted two research proposals: a $2.3M proposal to evaluate MPT's role in reducing unnecessary biopsies, with a decision expected in H1 2025, and a $1.1M proposal for validating the Mitomic Ovarian Test (MOT), which was not funded. IPO proceeds will fund the U.S. launch of Laboratory Developed Tests and drive global commercialization through partnerships and regulatory approvals.
Aditxt (NASDAQ: ADTX) has announced a virtual Fireside Chat scheduled for Friday, February 21, 2025, at 11:30 AM Eastern Time. CEO Amro Albanna will lead the session, providing updates on key corporate developments and the company's pipeline.
The discussion will focus on two main areas: Adimune, a subsidiary working on autoimmune conditions including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome, and Pearsanta's early cancer detection program and its planned IPO for 2025.
Participants can submit questions via email to engagement@aditxt.com by February 20th at 5:00 PM ET. Registration is available through the provided Zoom webinar link.
Aditxt (NASDAQ: ADTX) announced its Board of Directors has approved exploring an Initial Public Offering (IPO) for its subsidiary, Pearsanta, targeted for 2025. Pearsanta, a precision diagnostic company, specializes in early cancer detection through its proprietary Mitomic® Technology platform.
The proposed IPO aims to provide resources for Pearsanta's growth and expand its market presence globally. The company focuses on developing and commercializing early cancer detection solutions to support healthcare professionals in providing earlier and more accurate diagnoses.
This strategic move aligns with Aditxt's mission to accelerate promising health innovations and positions Pearsanta for a successful global launch of its cancer detection platform.
Evofem Biosciences (EVFM) reported Q3 2024 financial results, highlighting a 31% improvement in operating loss to $2.4 million compared to $3.6 million in Q3 2023. Net product sales decreased 12% to $4.5 million. The company acquired global rights to SOLOSEC, a single-dose oral antibiotic, and licensed Phexxi commercial rights in the Middle East. Total operating expenses decreased 20% to $6.9 million. Aditxt invested $5.0 million in Evofem since May 2024, including $1.3 million in Q3 and $2.7 million in October 2024.
Aditxt (NASDAQ: ADTX) announced a significant milestone in its acquisition plans for Appili Therapeutics (TSX: APLI; OTCPink: APLIF). At a special meeting, Appili's shareholders voted overwhelmingly in favor of a plan of arrangement that would allow Aditxt to acquire all issued and outstanding Class A common shares of Appili. This development marks a important step forward in Aditxt's strategy to expand its healthcare innovation platform.
Evofem Biosciences (OTCQB: EVFM) has secured voting agreements with Series E-1 stockholders and convertible noteholders to support its proposed merger with Aditxt's subsidiary Adifem. This follows Aditxt's recent $2.28 million investment in Evofem through Series F-1 convertible preferred stock, completing their total $5.0 million commitment since May 2024. The merger's closing conditions include majority shareholder approval and Aditxt raising approximately $17 million, with $15.2 million needed to satisfy Evofem's senior secured noteholder. The capital received has enabled Evofem to acquire SOLOSEC® and support Phexxi® initiatives targeting GLP-1 users.
Aditxt (NASDAQ: ADTX) has announced a significant development regarding its target acquisition, Appili Therapeutics (TSX: APLI; OTCPink: APLIF). The U.S. Food and Drug Administration (FDA) has provided positive feedback on the development strategy for ATI-1801, Appili's topical antiparasitic product. This feedback aligns with the requirements for the New Drug Application (NDA) submission.
Aditxt (NASDAQ: ADTX) has announced a virtual fireside chat on October 28, 2024, at 11:30 AM ET, featuring Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier, and moderated by Dr. Drew Pinsky. The event will focus on:
- Aditxt's acquisition of Evofem
- Post-acquisition plans for Evofem
- Aditxt's approach to accelerating innovations
The chat will highlight Evofem's evolution into a multi-product women's health franchise, including the re-launch of Solosec® and the planned launch of the Mitomic Endometriosis Test (MET™) in mid-2025. Aditxt estimates it will require $19.3 million to fund the Evofem acquisition, including $1.8 million for merger consideration and $2.28 million for additional Evofem stock purchase by October 31, 2024. An additional $15.2 million is needed to satisfy Evofem's Senior Secured Note at closing.
